Day One: Sleep quality must be taken seriously
A plenary session at the 58th Annual ESPE Meeting in Vienna, Austria, has highlighted how wide-ranging the risks associated with sleep and circadian rhythm disruption are.
Short stature management and growth hormone therapy in the Asia Pacific region Click here to view the full on-demand webcast This webcast will discuss the clinical approach to a child with s [...]
ESPE 2019
During ESPE 2019 in Vienna, medwireNews reported on original research and symposium discussions covering a wide range of topics including the management of Turner syndrome in adolescents and young adults, the dynamics of childhood obesity, e-reporting of rare endocrine conditions, genetic disorders of growth, the importance of sleep, and novel monogenic forms of autoimmune diabetes.
One in five childhood cancer survivors experience growth hormone deficiency
Growth hormone deficiency is common among childhood cancer survivors and is associated with the use of hypothalamic-pituitary radiotherapy, alkylating agents and intrathecal chemotherapy, as well as adverse health outcomes, say researchers.
Research focus: ‘Health not height’ – Trial results for a targeted treatment for children with achondroplasia
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosiritide in children with achondroplasia.
Growth hormone prescription differences highlighted for USA vs Europe
Data from two large observational studies show that children treated in the USA receive a higher dose of the commercial growth hormone somatropin and are taller, older, and more likely to be boys than girls relative to those treated in Europe.
C-type natriuretic peptide analogue increases growth velocity in children with achondroplasia
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Expert reviews: Dr Sasha Howard
Delayed puberty is common in the developed world, affecting over 2% of adolescents, and is associated with adverse health outcomes including short stature, reduced bone mineral density and compromised psychosocial health.
IMAGE 2019
This year the Insight for MAnaging Growth for Endocrine nurses (IMAGE) conference was held on 10-11th October 2019 at the Radison Blu Hotel, Bordeaux, France, The aims of the symposium were to provi [...]
GH therapy improves short-term emotional and social life quality for short stature children
Children with short stature show marked improvements in their emotional and social quality of life during their first year of treatment with growth hormone, study findings suggest.